INDIANAPOLIS (AP) ¿ Eli Lilly & Co. is ready to buy again, four months after closing its largest acquisition ever, the $6 billion-plus purchase of cancer drug maker ImClone Systems Inc.

Lilly Chief Executive John Lechleiter told The Wall Street Journal his company will pursue deals that cost between $5 billion and $15 billion but will shy away from bigger acquisitions.

The company also plans to stick to drugs, Lechleiter told the Journal, saying Lilly isn't interested in medical device or diagnostic companies.

He said Lilly wants to expand its animal-health business and also will consider the biotechnology sector.

A run of major deals has swept through the drug industry this year. New York-based Pfizer Inc. said in January it agreed to buy Madison, N.J.-based rival Wyeth for $68 billion.

Swiss pharmaceutical giant Roche paid $46.8 billion in cash to buy the 44 percent of California-based biotech pioneer Genentech that it didn't already own.

Whitehouse Station, N.J.-based Merck & Co. will pay $41.1 billion to buy Kenilworth, N.J.-based Schering-Plough Corp.

If you liked this article you might like

What's Behind the Surge in Energy Stocks

Hillary Clinton Says Prosecuting Individuals is Key to Wall Street Reform